ORTRIMEF

This brand name is authorized in Nigeria.

Active ingredients

The drug ORTRIMEF contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII C7D6T3H22J - ARTEMETHER
 

Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
 
Read more about Artemether
2
UNII F38R0JR742 - LUMEFANTRINE
 
Read more about Lumefantrine

Packages

This drug has been approved in Nigeria as follows:

Identifier Form Presentation Description Approval
A11-1287 Tablet Ortrimef 80/480 Tablets TAB 80 mg; 480 mg 1 X 8 Ortrimef 80/480 Tablets A11-1287 Ortrimef ARTEMETHER, LUMEFANTRINE ANTIMALARIA ARTEMETHER 80MG, LUMEFANTRINE 480MG TABLETS 1 X 8 OVER THE COUNTER TREATMENT OF UNCOMPLICATED MALARIA CAUSED BY PLASMODIUM FALCIPARUM ORFEMA PHARMACEUTICAL INDUSTRY LIMITED NIGERIA ORFEMA PHARMACEUTICAL INDUSTRY LIMITED NIGERIA 08/25/2022 08/24/2027 25/08/2022
A4-9435 Tablet ORTRIMEF TABLET TAB 20 mg; 120 mg 1X24. 1X18, 1X12, 1X6 RNW-PP-216504 ORTRIMEF TABLET A4-9435 ARTEMETER+LUMENFANTRINE Drugs 24 N/A 1X24. 1X18, 1X12, 1X6 TABLET ORFEMA PHARMACEUTICAL INDUSTRY LIMITED 14537852 info@orfema.com 5, ATILADE ADEBOWALE STREET, OFF DADDY SAVAGE ROAD, OFF IJU ROAD Nigeria ORFEMA PHARMACEUTICAL INDUSTRY LIMITED Renewal 8033265151 degunite2000@yahoo.com 5, ATILADE ADEBOWALE STREET, FAGBA – IJU, LAGOS STATE. 22/12/2023 20/12/2028 21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
P01BF01 Artemether and lumefantrine P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BF Artemisinin and derivatives, combinations
Discover more medicines within P01BF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
NG Registered Drug Product Database A11-1287, A4-9435

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈